Search

Biogen Alzheimer’s failure drags down Biotech Growth – Biogen, a key holding in Biotech Growth Trust and a component of most other biotech and healthcare portfolios, has lost a third of its value after trials of an Alzheimer’s drug failed to show any benefit. Biogen and its partner, Japanese drugmaker Eisai, said they would stop […]

Biotech Growth blames large caps for 2017/18 under-performance OrbiMed-managed Biotech Growth Trust (BIOG) blamed an overweight position in large cap stocks for under-performance against the benchmark Nasdaq Biotechnology index (NBI) in the six months to March 2018 and financial year as a whole, having recorded a 6.7% fall in NAV against a 2.2% fall for […]

Biotech Growth doubles down on Biogen and Alexion OrbiMed-managed Biotech Growth Trust (BIOG) appears to have increased its already substantial positions in Biogen and Alexion and reduced (or possibly even sold) its previously large stake in Regeneron in the last month, according to its an analysis of its top holdings by Marten & Co. The […]

Biotech Growth sells Amgen, buys Regeneron and Alexion in March OrbiMed-managed Biotech Growth Trust (BIOG) sold a large proportion of its stake in Amgen last month, while increasing its holdings in Regeneron and Alexion, according to an analysis of its top holdings disclosed in its latest factsheet. The shareholding in Amgen, which accounted for just over 10% of […]

Biotech Growth’s big-bio focus a cause of underperformance in February OrbiMed-managed Biotech Growth Trust (BIOG) saw a 3.9% fall in its NAV in February, under-performing against a 2.6% decline in the sterling-denominated value of the benchmark NASDAQ Biotechnology Index. The value of investments held by the trust were hit in the market wide sell-off in […]

Biotech Growth notches up small rise in Jan, but outlook for Feb is weaker Orbimed-managed Biotech Growth Trust (BIOG) notched up a broadly in-line performance in the otherwise strong month of January, despite seeing a major setback for one of its top 10 holdings. However, its outlook for February is looking weaker, an analysis by Marten […]

Contrasting movements likely for Biotech Growth Trust investees Orbimed-managed Biotech Growth Trust (BIOG) looks set to see some contrasting fortunes for key investments in its January update, due in the middle of next month, but could nevertheless be able to offer investors a positive report.  On the plus side, the trust will have seen its investment […]

Biotech Growth Trust swaps out Celgene and Alexion for Amgen OrbiMed, the manager of the UK’s Biotech Growth Trust BIOG, has boosted the trust’s investment in Amgen at the expense of previous long-term holdings in Celgene and Alexion over the last month, according to the November portfolio update. Amgen is now the trust’s joint second largest investment (at 10% […]

Biotech Growth manager denies allegations – The board of The Biotech Growth Trust says that it notes that the General Partners of OrbiMed Capital LLC, which acts as portfolio manager to the company, released a statement late on 5 December concerning founding partner Samuel Isaly, who is the subject of a press article containing allegations of […]

Biotech Growth lags benchmark but shareholders still make 28%. Biotech Growth says that it produced a good return in absolute terms for the year ended 31 March 2017. The net asset value per share rose by 27.5% during the year, which compares with the  benchmark, the NASDAQ Biotechnology Index (sterling adjusted), which rose by 29.2%. As […]